Compound Radar

Repligen Corporation (RGEN) Stock Analysis

Price $168.53
Market cap $9.51B
Next earnings Nov 3, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

67
67/100 Good Quality
  • Financial Health 60
  • Profitability 65
  • Business Quality 75
  • Balance Sheet 65
  • Cash Flow 80

Why this rating?

Health 67/100 — Good Quality

Strongest Cash Flow 80/100
Softest Financial Health 60/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Repligen Corporation (RGEN) is a Medical Instruments & Supplies company in the Healthcare sector. Compound Radar rates Repligen Corporation 67/100 (Good Quality) due to high business quality, steady revenue growth, and manageable leverage.

Investment profile

  • Quality High
  • Growth Moderate
  • Balance Sheet Adequate
  • Valuation Elevated

Financial highlights

Valuation

  • P/E 227.74
  • Forward P/E 63.9
  • PEG 1.67
  • EV/Revenue 11.9

Profitability

  • Revenue Growth 11.9%
  • Gross Margin 53.8%
  • Operating Margin 9.3%
  • Net Margin 5.3%
  • ROE 2.0%

Financial strength

  • Cash $810.45M
  • Debt $690.94M
  • Net Cash $119.51M
  • Free Cash Flow $91.69M
  • Current Ratio 9.05

Similar companies

Peers in Medical Instruments & Supplies, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Medical Instruments & Supplies →

FAQ

How Compound Radar scores and tracks Repligen Corporation (RGEN).

View Methodology & FAQ →